BioSpace News Archive

BioTek’s Synergy™ Neo2 Hybrid Multi-Mode Microplate Reader received expanded certification from Cisbio Bioassays for their proprietary HTRF® technology, a TR-FRET assay platform used in the Life Sciences.

Evotec SE announced that the Company successfully issued a Schuldschein of EUR 250 m on the capital market.

Aurinia Pharmaceuticals Inc. is pleased to announce that shareholders of the Company elected all eight of the Company’s highly qualified director nominees at the Company’s Annual General Meeting held on June 26, 2019.

Motus GI Holdings, Inc. announced the pricing of its underwritten registered public offering of 6,666,667 shares of its common stock, offered at a price to the public of $3.00 per share for expected gross proceeds of $20.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

Gamida Cell Ltd. announced the pricing of an underwritten public offering of 7,000,000 ordinary shares at a public offering price of $5.00 per share for aggregate gross proceeds of $35 million, before deducting underwriting discounts and commission and estimated offering expenses.

Yisheng Biopharma Co., Ltd. announced that it has received Investigational New Drug clearance from the National Medical Products Administration of China to initiate a clinical trial of YS-ON-001, a first-in-class immuno-oncology product for the treatment of advanced solid tumors.

Partnership to provide B2B ground transportation solutions for customers in need of non-medical travel assistance from transportation hubs across the world

Agendia, Inc., a world leader in precision oncology, announced today that its MammaPrint Breast Cancer Risk-of-Recurrence Test is the only molecular diagnostic indicated for use with patients who have breast cancer that has spread to their lymph nodes according to the updated Cancer Care Ontario Guidelines.

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Victor Paulus, Ph.D. as Senior Vice President, Regulatory Affairs.

PharmaMar (MSE:PHM) will hold today its Annual General Shareholders’ Meeting in Vigo (Spain) today, where it will review the 2018 financial year, the Company’s most important milestones and future plans, particularly in the oncology area, where the bulk of the Group’s activity is carried out.